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Abstract
Background: Alternative Promoter (AP) usages have been shown to enable diversified transcriptional regulation of
individual gene in a context-specific (e.g., pathway, cell lineage, tissue type, and development stage et. ac.) way. Aberrant
uses of APs have been directly linked to mechanism of certain human diseases. However, whether or not there exists a
general link between a gene’s AP repertoire and its expression diversity is currently unknown. The general relation between
a gene’s AP repertoire and its disease susceptibility also remains largely unexplored.
Methodology/Principal Findings: Based on the differential expression ratio inferred from all human microarray data in NCBI
GEO and the list of disease genes curated in public repositories, we systemically analyzed the general relation of AP
repertoire with expression diversity and disease susceptibility. We found that genes with APs are more likely to be
differentially expressed and/or disease associated than those with Single Promoter (SP), and genes with more APs are more
likely differentially expressed and disease susceptible than those with less APs. Further analysis showed that genes with
increased number of APs tend to have increased length in all aspects of gene structure including 39 UTR, be associated with
increased duplicability, and have increased connectivity in protein-protein interaction network.
Conclusions: Our genome-wide analysis provided evidences that increasing alternative promoter repertories is positively
associated with differential expression and disease susceptibility.
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Introduction
Promoter is the region of DNA consisting of transcriptional
regulatory elements required for transcription initiation. Alterna-
tive Promoter (AP) usage refers to the control of alternative
transcriptional start within a single gene locus by using alternative
promoter. AP usage has been observed for many individually
characterized genes [1,2] and recent genomic studies have found
that approximately 50% of human genes have at least one AP
[3,4]. The wide-spread AP usage indicates it might play a critical
role in shaping human genome and transcriptome [1,2,5,6].
As AP consists of different modules of cis-regulatory elements
[7,8], AP usage has long been explored for the regulation of
expression diversity of individual metazoan gene [9]. For example,
by selectively using one promoter active in parotid gland and the
other active in liver, mammal a-amylase gene shows a more than
100-fold difference of expression level in these two tissues [10].
The number of individually characterized genes with AP driving
context-specific (e.g., pathway, cell line, tissue type, development
stage, species et. ac.) manner of differential expression has
accumulated during the past two decades [1,2,5,6,11,12]. This
thus raises an interesting question: are genes with AP more likely
to be differentially expressed than genes with Single Promoter
(SP)? Furthermore, among genes with AP, are genes with more AP
more likely to be differentially expressed?
There is also growing evidence that AP usage is linked to disease
through aberrant promoter choice and/or genetic defects affecting
the functional cis-regulatory element [2,9]. For example, the
upstream promoter of MYC, dominant negative in normal tissue, is
aberrantly activated in Burkitt’s lymphoma cells due to aberrant
translocation of MYC gene locus [13]. A recent survey of
mammalian AP showed that the group of putative human cancer
related genes (,2,800) on average have 2 promoters compared
with an average 1.5 promoters among the other human genes [2].
However, cancer related genes can be classified into passenger and
driver, with the later playing a critically causal instead of passive
role in tumor formation and progression [14,15]. It remains
unclear whether there is a general link between a gene’s AP
repertoire and the likelihood of being cancer driving genes.
Furthermore, it remains unclear whether or not there is a positive
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likelihood of being associated with general human diseases.
Results
AP Genes Are More Likely to Be Differentially Expressed
For each human gene, we obtained its Differential Expression
Ratio (DER) from the study by Chen et al. [16,17]. The DER
value of a gene is its frequency of differential expression in multiple
microarray studies (see Methods section). As DER was derived
from all available human microarray datasets deposited at GEO, it
provided a comprehensive metric to measure the regulation
diversity at expression level. To test the hypothesis whether genes
with AP are more likely differentially expressed than genes with
SP, we compared the DER between SP and AP genes. Of the
genes with SP, the median DER was 0.50. In contrast, the genes
with AP have median DER 0.53 (P,2.2e-16, Wilcox rank sum
test). To test whether there is a general link between increasing
number of promoter and differential expression among genes with
AP, we divided the AP genes into three classes based on their
number of promoters (AP=2, AP=3/4, AP.=5, see methods).
As shown in Figure 1, genes with more AP are more likely to be
differentially expressed. The median DER was 0.52 for AP=2
class (P=2.2e-16, vs. SP), and increased to 0.54 for AP=3/4 class
(P,2.2e-16, vs. AP=2 class). The median DER was further
increased to 0.56 for AP.=5 class (P,2.2e-16, comparing with
that of AP=3/4 class). Recent studies have shown that different
tissues, cell types, developmental and/or disease stage are often
regulated by distinct transcriptional factors, and there is
considerable diversity in the composition of cis-regulatory elements
in alternative promoters [2,7,18]. The increased number of
alternative promoters from a single locus will provide increased
flexibility and diversity of AP usage, and thereby generate either
identical or distinct protein conducts in a tissues, cell lineage, stage,
and time point specific manner. Such a diversifying and complex
regulation control might contribute to the increased frequency of
differential expression observed here for AP genes.
AP Genes Are More Likely to Be Disease Susceptible
The study by Chen et al [17] has revealed that highly
differentially expressed genes are more likely to be associated
with disease. As we found that AP genes are more likely to be
differentially expressed, it is expected that AP genes are more likely
to be involved in disease. To confirm this positive link and quantify
the extent to which a gene’s promoter repertoire is associated with
the likelihood of disease susceptibility, we first compiled a list of
775 human cancer genes which are likely to play casual roles in
tumor formation and progression. We built a 262 contingency
table using the number of cancer-driver gene and non-cancer-
driver genes, and tested whether the fraction of cancer-driver
genes is significantly increased from SP to AP gene classes using
Fisher’s exact test. As shown in Figure 2, the fraction of cancer-
driver genes in SP class was 2.9%, and increased to 5.8% in AP
class, an almost 2-fold increase (P=2.2e-16). We further compare
the fraction of cancer-driver genes between different AP classes.
The fraction was found to be 4.3% for AP=2 class (P=0.00021,
vs. SP), 6.2% for AP=3/4 class (P=0.00026, vs. AP=2), and
9.7% for AP.=5 class (P=8.075e-05, vs. AP=3/4).
In order to further characterize the general relationship between
having increased promoter repertoire and the likelihood of being
human disease susceptibility gene, we compiled a list of 3,392
curated human disease-associated genes. We again built 262
contingency tables and tested whether there is an increased
fraction of disease gene from SP to AP gene classes using Fisher’s
exact test. As shown in Figure 3, the fraction of disease genes in SP
class was 16.4%, and increased to 21.6% in AP class (P=2.78e-
16). The fraction was 19.9% for AP=2 class (P=2.497e-06, vs.
SP), 21.7% for AP=3/4 class (P=0.04481, vs. AP=2), and 26.6%
for AP.=5 class (P=0.0004199, vs. AP=3/4).
Figure 1. Distribution of differential expression ratio for each
gene class. The figure (density plot) showed that genes with more
alternative promoters are more likely to be differentially expressed. SP
means gene with single promoter, while AP=2, AP=3,4, and AP.=5
means gene with only 2 promoters, 3 or 4 promoters, and at least 5
promoters, respectively.
doi:10.1371/journal.pone.0009482.g001
Figure 2. Fraction of cancer driver genes for each gene class.
The figure showed that genes with more alternative promoters tend to
be enriched with cancer driver gene. The Y-axis is the fraction of genes
belonging to cancer driver gene in each gene class. SP means gene with
single promoter while AP means gene with alternative promoters.
AP=2, AP=3,4, and AP.=5 means gene with only 2 promoters, 3 or
4 promoters, and at least 5 promoters, respectively.
doi:10.1371/journal.pone.0009482.g002
Promoter and Disease
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As shown in Table 1 and Figure S1, AP genes are significantly
longer than SP genes in all aspects of the gene structure including
genomic sequence, coding sequence (CDS), 59 untranslated
regions (59 UTR), 39 UTR, total exon, and total intron. AP genes
also tend to have more exons and introns. Among AP genes, the
class with more AP tends to be longer in all aspects of gene
structure than the class with less AP (Table 1 and Figure S1). For
example, the median of total intron length is 14.4, 25.2, 43.7 and
87.2 kb for SP, AP=2, AP=3,4 and AP.=5 gene class,
respectively (P,2.2e-16, Wilcox rank sum test). As AP usage will
lead to alternative usage of first exon, the increased number of AP
will undoubtedly increase the degree of freedom for the extension
of transcript region from the 59 end [3]. However, it is remarkable
that 39 UTR, the region enriched for microRNA binding sites
important for post-transcriptional regulation, also tend to be
longer as the number of AP increases (Figure 4).
AP Genes Are Associated with Increased Duplicability
We retrieved 14, 410 unique duplicate genes and 5, 226 unique
singleton genes from Ensembl database via BioMart, with the
fraction of duplicate gene about 73%. 10,665 of duplicate genes
and 4,054 of singleton genes have curated promoter architecture
from DBTSS (used in this work), with a similar ratio of duplicate
gene (i.e, 72.5%). As shown in Figure 5, duplicate genes comprise
67% of SP genes, but make up 77% of AP genes (P=1.087e-07,
Fisher’s exact test). The fraction was 74% for AP=2 class
(P=0.002138, vs. SP), 78% for AP=3/4 class (P=0.08113, vs.
AP=2), and 85% for AP.=5 class (P=0.05049, vs. AP=3/4).
AP Genes Are More Likely to Be Associated with Hub
We downloaded the manually curated human protein–protein
interaction network from HPRD[19]. We found that the AP genes
tend to have significantly more node connectivity (degree) than
that of SP genes, and display a much stronger trend as the number
of AP increases (Figure 6, P,=0.01, Wilcoxon rank sum test).
The average connectivity of SP genes is 6.5, and increases to 10.5
for AP.=5 gene class (P,2.2e-16).
Example of AP genes. To exemplify the characters of AP
genes studied in this work, we described several genes whose
alternative promoter usage has been shown in literatures. GNAS
(guanine nucleotide binding protein, alpha stimulating activity
polypeptide 1), is a G protein involved in hormonal regulation of
adenylate cyclase. GNAS has ten potential alternative promoters
supported by curated full-length c-DNA clones, and the switched
recruitment of four of them has been found to generate multiple
Figure 3. Fraction of disease genes for each gene class. The
figure showed that genes with more alternative promoters tend to be
enriched with disease gene. The Y-axis is the fraction of genes
belonging to disease gene in each gene class. SP means gene with
single promoter while AP means gene with alternative promoters.
AP=2, AP=3,4, and AP.=5 means gene with only 2 promoters, 3 or
4 promoters, and at least 5 promoters, respectively.
doi:10.1371/journal.pone.0009482.g003
Table 1. Length parameter of each gene class.
Genomic Sequence CDS 59 UTR 39 UTR Total Exon Total Intron # of Exon # of Intron
SP 16,835
a 1,097 139 599 2,158 14,370 6
b 5
AP 41,017 1,638 183 1,062 3,274 37,314 11 10
Pvalue
c ,2.2e-16
* ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16
AP=2 28,100 1,415 172 881 2,808 25,162 9 8
Pvalue
d ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16
AP=3,4 48,058 1,763 188 1,178 3,492 43,650 12 11
Pvalue
e ,2.2e-16 ,2.2e-16 2.153e-05 ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16
AP.=5 90,787 2,296 207 1,325 4,178 87,204 17 16
Pvalue
f ,2.2e-16 ,2.2e-16 0.000329 0.0005684 ,2.2e-16 ,2.2e-16 ,2.2e-16 ,2.2e-16
The table showed that genes with more alternative promoters tend to have increased length in all aspects of gene structure parameter. SP means gene with single
promoter while AP means gene with alternative promoters. AP=2, AP=3,4, and AP.=5 means gene with only 2 promoters, 3 or 4 promoters, and at least 5
promoters, respectively.
a: Median length;
b: Median count;
c: Wilcoxon rank sum test, AP vs. SP.
d: Wilcoxon rank sum test, AP=2 vs. SP.
e: Wilcoxon rank sum test, AP=3,4 vs. AP=2.
f: Wilcoxon rank sum test, AP.=5vs. AP=3,4.
*: The Wilcoxon rank sum test function in R (wilcox.test) returns ‘‘P,2.2e-16’’ when P is smaller than 2.2e-16.
doi:10.1371/journal.pone.0009482.t001
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development (For reviews, see Weinstein et al. [20] and
Davuluri et al. [2]). GNAS has a high frequency of differential
expression - differentially expressed in more than 69% of GEO
dataset in which it was measured (DER value equals to 0.691).
Promoter switching of GNAS has been found to plays a role in
various diseases and tumorigenesis through loss of imprinting
[21,22,23]. It is a disease gene of multiple syndromes including
Albright hereditary osteodystrophy, pseudopseudohypoparathyroidism
and McCune-Albright syndrome [24,25]. It is a cancer driver gene of
pituitary adenoma [26]. It is a duplicate gene, and the paralog is
GNAL. The gene length of RUNX1 is 71.5 kb, well above the median
of SP gene (16.8 kb). GNAS has 23 interacting partners in the protein-
protein interaction network, comparing with an average connectivity of
6.5 for SP genes.
FGFR1 (fibroblast growth factor receptor 1), is a member of the
fibroblast growth factor receptor family that binds to both acidic
and basic fibroblast growth factors. FGFR1 has seven alternative
promoters supported by curated full-length c-DNA clones, and at
least of four of them have been shown to control the differential
expression in a tissue- and cancer cell- specific manner
[27,28,29,30]. We found that FGFR1 is indeed frequently
differentially expressed, with the DER value of 0.684. It is a
disease gene of a number of syndromes including familial Pfeiffer
syndrome [31]. It is cancer driver gene, implicated in the
tumorigenesis of hematological malignancies including chronic
myeloid leukemia, myeloid hyperplasia and non-Hodgkin’s
lymphoma [32]. It is a duplicate gene, with its paralogs including
RET and FGFR2. FGFR1 has 18 exons and 5.9 kb exon length,
comparing with the 6 exons and 2.2 kb exon length for SP gene.
The protein-interaction network connectivity of FGFR1 is 36.
PDGFRA (platelet-derived growth factor receptor, alpha
polypeptide), is a cell surface tyrosine kinase receptor for members
of the platelet-derived growth factor family. The expression of
PDGFRA is regulated by four potential alternative promoters, and
the switched usage of two of them has been found to be involved in
early human embryogenesis [33,34]. The DER value of PDGFRA
is 0.651, indicating that it is differentially expressed in more than
65% of GEO dataset in which it was measured. It is a key disease
Figure 5. Fraction of duplicate genes for each gene class. The
figure showed that genes with more alternative promoters tend to have
increased duplicability. The Y-axis is the fraction of genes belonging to
duplicate gene in each gene class. SP means gene with single promoter
while AP means gene with alternative promoters. AP=2, AP=3,4, and
AP.=5 means gene with only 2 promoters, 3 or 4 promoters, and at
least 5 promoters, respectively.
doi:10.1371/journal.pone.0009482.g005
Figure 6. Distribution of node connectivity (degree) for each
gene class in human protein-protein interaction network. The
figure (density plot) showed that genes with more alternative
promoters tend to have increased node connectivity. SP means gene
with single promoter, while AP=2, AP=3,4, and AP.=5 means gene
with only 2 promoters, 3 or 4 promoters, and at least 5 promoters,
respectively.
doi:10.1371/journal.pone.0009482.g006
Figure 4. Length distribution for the 39 un-translated region (39
UTR) of each gene class. The figure (density plot) showed that genes
with more alternative promoters tend to have longer 39 UTR. SP means
gene with single promoter, while AP=2, AP=3,4, and AP.=5 means
gene with only 2 promoters, 3 or 4 promoters, and at least 5 promoters,
respectively.
doi:10.1371/journal.pone.0009482.g004
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associated with the hypereosinophilic syndrome [35,36]. It also
serves as a well-documented cancer driver gene of gastrointestinal
stromal tumor [37]. The paralog of PDGFRA, PDGFRB, has two
alternative promoters and is also a cancer driver gene [38].
Compared with SP genes, PDGFA is both longer (69.1 kb) and
connected by more interacting partners (24) in the protein-protein
interaction network.
Discussion
The functional role of alternative promoter usage in differential
expression and/or disease susceptibility has been characterized for
a bunch of genes. However, whether there is a positive link
between a gene’s AP repertoire and its likelihood of being
differentially expressed and/or disease associated remains un-
known. Based on a systematic analysis of promoter, microarray
and disease gene in the public repositories, we found that
compared with single-promoter genes, genes with alternative
promoters are more likely to be differentially expressed and/or
disease associated. Furthermore, our results showed that among
AP genes, those with more promoters are more likely differentially
expressed and/or disease susceptible.
Gene expression data has been frequently incorporated into the
prioritization of disease candidate genes or SNPs. Recent
translational study by Chen et al [17] has demonstrated that
highly differentially expressed genes are more likely to have
variants associated with disease, based on the analysis of all
microarray data from GEO database. The finding that there is a
positive association between differential expression and disease
susceptibility marked a significant step towards the translation of
gene expression data into disease gene prioritization. However, the
molecular, genetic and genomic mechanism underlying this
translation remains to be explored. Our study found that there
is a general link between alternative promoter and differential
expression and disease susceptibility. We further demonstrate that
genes with increased number of alternative promoters are marked
with features important to regulation complexity and disease
origins, including increased gene length, duplicability and
connectivity. While it remains to be explored for the positive
prediction value of incorporating alternative promoter repertoire
into disease gene prioritization, our results will be useful to
understand the genomic mechanism underlying the translation
from differential expression to disease susceptibility.
A better characterization of the role of alternative promoter
usage on expression diversity and disease susceptibility requires a
truly unbiased and comprehensive resource of alternative
promoter activity, gene expression change and disease propensity.
The DBTSS full-length cDNA derived alternative promoter data
are taken from .160 distinct cDNA library of various cell types
and tissue, and the GEO derived DER data are calculated based
on 4,877 group-versus-group comparisons on 476 human GEO
datasets. Although comprehensive, there is a possibility that both
DBTSS and GEO data might be biased to certain biological
niches. Thus, a future research direction will be to identify the
separated effects in the analysis of alternative promoter versus
differential expression, by classifying the different kinds of
experiment in DBTSS and GEO (e.g., based on tissue, disease
condition, and et. ac.). Also, it remains to be explored the effects of
adopting alternative metric of differential expression and different
definition of alternative promoters (e.g., varied cutoff of TSS
clustering, other curated promoter database [39], and et. ac.).
Similarly, the OMIM-based disease gene record is far from
complete and historically biased to monogenic disorders. A more
complete catalog of genes underlying different disease will alleviate
the potential analysis bias to certain type of human disorders.
Recent technique developments in high-density promoter
microarray and next-generation sequencing have enabled the
genome-wide monitoring of alternative promoter activity and
transcriptome change under different conditions [5,6,40,41,42].
Simultaneously, results from multiple genome wide association
studies have shed light to the widespread involvement of
regulatory variants including alternative promoters in disease
association [43,44,45,46]. By integrating the fast-accumulated
data from these high-throughput studies and other functional
genomics data, we expect that a more complete understanding of
the mechanism of and extent to which alternative promoter usage
has shaped human transcriptome and diseasome will be achieved.
In summary, based on a systematic analysis of promoter,
microarray and disease gene in public repositories, we demon-
strated that there exists a general link between a gene’s alternative
promoter repertoire and its expression diversity and/or disease
susceptibility. Our further comparative analyses of AP vs. SP gene
reveal several remarkable features of AP genes as a class. First, we
found that AP genes tend to have longer length in all aspects of
gene structure. As gene length is found to be positively related with
the density of functional elements [47], it is reasonable to suggest
that AP genes, with increased length in all aspects of gene
parameter, subject to more sophisticated regulation besides
transcriptional factor mediated promoter binding (e.g., alternative
splicing [1,48], microRNA mediated regulation [49,50,51], and et.
ac.). Second, we showed that AP genes are associated with
increased duplicability. Gene duplication has been widely
appreciated as one of the factors underlying genetics variation,
phenotypic diversity and disease mechanism [52]. Third, we
observed that AP genes tend to have higher connectivity in
protein-protein interaction network. The topological centrality of
AP genes thus indicates that they play critical role in human
physiological system [53]. Collectively, our analysis suggests that
increasing AP repertories might be an important factor in shaping
human genome, transcriptome and diseasome.
Methods
We retrieved information of promoter annotation from DBTSS
(Version 6.0, based on UCSC hg18) [54]. DBTSS determine
alternative promoters using clustering of transcriptional start sites
(TSS) by 500 bps, with TSS derived from collection (.160 distinct
libraries) of experimentally determined 59-end sequences of full-
length cDNA clones. A total of 15,180 human RefSeq genes with
curated full-length cDNA derived promoter architecture were
obtained, which include 7,291 genes with Single Promoter (SP)
and 7,889 genes with Alternative Promoter (AP). Among genes
with AP, there are 3, 772 genes with two promoters (AP=2), 2,941
with three or four (AP=3,4), and 1,176 with five or more
(AP.=5). The length parameter of gene structure was based on
NCBI Reference Sequence (RefSeq) annotation. The 59 UTR
length is calculated from transcription start position and cording
region start, while that of 39 UTR from transcription end position
and cording region end. For genes with multiple transcripts, the
longest one is selected for length calculation.
We obtained the differential expression ratio (DER) of human
genes from the study by Chen et al. [16,17]. Briefly, the authors
downloaded all curated human microarray-based gene expression
datasets from the NCBI Gene Expression Omnibus (GEO)
[55,56], and conducted comprehensive group-versus-group com-
parisons within each dataset based on GEO annotated experi-
mental variables (e.g., time, treatment, tissue, development stage et
Promoter and Disease
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[57]) genes. For each human gene, the DER was calculated as the
count of GEO datasets in which it was differentially expressed
divided by the count of GEO datasets in which it was measured
[17]. Only genes that were measured in at least 5% of all GEO
datasets are included, which include 14,783 (97.4%) of the 15,180
genes with promoter annotations available from the DBTSS
database.
We downloaded a manually curated collection of ,380 human
genes whose variants play a causal role in cancer (Cancer Gene
Census database [14]). CGC is a regularly updated database to
catalogue those genes for which mutations, deletions, and/or
translocations have been causally implicated in cancer. We also
compiled a set of ,450 human cancer candidate genes, which are
most likely to be key driver genes, based on recent large-scale
sequencing of breast, colorectal, pancreatic and brain tumor
genomes [15,58,59,60]. The combination of these two datasets
resulted in a list of 775 unique cancer driver genes.
We compiled a list of ,2,380 known disease genes from the
Morbid Map (MM) of the Online Mendelian Inheritance in Man
(OMIM) [61]. Only the Morbid Map entries with the ‘‘(3)’’ tag, for
which there is strong evidence that abnormality of the particular
gene is causative to the disorder, were used to derive the list of
human disease gene. We also downloaded a list of ,2,360 human
genes with annotated disease-associated variants from the latest
Swiss-Prot database [62]. A combination of these two dataset
resulted in 3,392 non-redundant human disease genes.
We used BioMart [63]to retrieve the complete set of human
duplicate genes from EnsemblCompara GeneTrees database[64].
This corresponds to a total of 14,410 unique genes that have at
least one duplicate copy in the human genome, and a total of
5,226 unique known singleton genes that have no duplicate copy.
We downloaded the manually curated human protein–protein
interaction network from the Human Protein Reference Database
[19], which is composed of 9,306 unique proteins and 35,023
protein–protein interactions (with self-interaction removed). The
network degree was calculated using the NetworkAnalyzer plug-in
[65] of Cytoscape package [66].
Supporting Information
Figure S1 Length distribution for the gene structure parameter
of each gene class. The figure (density plot) showed that genes with
more alternative promoters tend to be longer in all aspects of gene
structure. SP means gene with single promoter, while AP=2,
AP=3,4, and AP.=5 means gene with only 2 promoters, 3 or 4
promoters, and at least 5 promoters, respectively.
Found at: doi:10.1371/journal.pone.0009482.s001 (0.27 MB
PDF)
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